Gisondi P, et al. - A retrospective observational study was conducted to determine the utiity of secukinumab administered without the initial loading dose in patients with psoriasis. For this study, a sum of 156 individuals were enrolled. They investigated efficacy by comparing the Psoriasis Area and Severity Index (PASI) 75 and PASI 90 response rates at week 8, 12, 16, 32 and 48. For patients who received the labelled dose, in comparison with those who did not, PASI 75 response rates were achieved at week 8, 12, 16, 32 and 48 by 60% vs. 40%, 72% vs. 61%, 77% vs. 75%, 85% vs. 77% and 79% vs. 78%, respectively. Especially those with body weight greater than 80 kg, a greater proportion of patients receiving secukinumab without the loading dose discontinued treatment because of inefficacy. An association was found between secukinumab administered without the loading dose and a higher proportion of primary inefficacy, and achieved inferior results compared with the labelled dose at week 8 and week 12, but indicated similar efficacy thereafter.